{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:51:34Z","timestamp":1791287494958,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":2685,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1038\/mt.2009.37","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T11:28:14Z","timestamp":1236684494000},"page":"954-963","source":"Crossref","is-referenced-by-count":168,"title":["Glycoengineered Acid \u03b1-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Yunxiang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan K","family":"Gumlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Bercury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M","family":"Canfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Mattaliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2009.37_bib1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.tibtech.2003.09.002","article-title":"Sugar coating extends half-lives and improves effectiveness of cytokine hormones","volume":"21","author":"Koury","year":"2003","journal-title":"Trends Biotech"},{"key":"10.1038\/mt.2009.37_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nbt799","article-title":"Enhancement of therapeutic protein in vivo activities through glycoengineering","volume":"21","author":"Elliott","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2009.37_bib3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nbt0987-953","article-title":"A modified human tissue plasminogen activator with extended half-life in vivo","volume":"5","author":"Lau","year":"1987","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2009.37_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0304-4165(81)90474-8","article-title":"Uptake and biodistribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation","volume":"673","author":"Furbish","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2009.37_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/BF00711365","article-title":"Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease","volume":"17","author":"Brady","year":"1994","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2009.37_bib6","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1038\/mt.2009.37_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"Van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/mt.2009.37_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"Van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1038\/mt.2009.37_bib9","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2009.37_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00005792-199505000-00002","article-title":"Clinical variability in adult-onset acid maltase deficiency; report of affected sibs and review of the literature","volume":"74","author":"Felice","year":"1995","journal-title":"Medicine"},{"key":"10.1038\/mt.2009.37_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s100480050030","article-title":"Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients","volume":"1","author":"Vorgerd","year":"1998","journal-title":"Neurogenetics"},{"key":"10.1038\/mt.2009.37_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T\u2192G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology"},{"key":"10.1038\/mt.2009.37_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid \u03b1-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2009.37_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073807302598","article-title":"Long-term enzyme replacement therapy for Pompe disease with recombinant human \u03b1-glucosidase derived from Chinese hamster oveary cells","volume":"22","author":"Rossi","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1038\/mt.2009.37_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","article-title":"Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease","volume":"18","author":"Van Capelle","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1038\/mt.2009.37_bib16","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphat receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem Int"},{"key":"10.1038\/mt.2009.37_bib17","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose 6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J Clin.Endocrinol Metab"},{"key":"10.1038\/mt.2009.37_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: new twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat Rev"},{"key":"10.1038\/mt.2009.37_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid \u03b1-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2009.37_bib20","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid \u03b1-glucosidase improves the clearance of glycogen in Pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.37_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid \u03b1-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem J"},{"key":"10.1038\/mt.2009.37_bib22","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1016\/S0021-9258(18)92727-4","article-title":"Human lysosomal \u03b1-glucosidase. Characterization of the catalytic site","volume":"266","author":"Hermans","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.37_bib23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2009.37_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of \u03b1-galactosidase A","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.37_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2008.010","article-title":"Ability of AAV8-mediated hepatic expression of acid \u03b1-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice","volume":"6","author":"Ziegler","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2009.37_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing \u03b1-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.37_bib27","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"key":"10.1038\/mt.2009.37_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","article-title":"Glycogen stored in skeletal but not in cardiac muscle in acid \u03b1-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme","volume":"6","author":"Raben","year":"2002","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.37_bib29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/nbt1252","article-title":"Post-translational modifications in the context of therapeutic proteins","volume":"24","author":"Walsh","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2009.37_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1039\/b614939c","article-title":"Metabolic oligosaccharide engineering: perspectives, applications, and future directions","volume":"3","author":"Campbell","year":"2007","journal-title":"Mol Biosyst"},{"key":"10.1038\/mt.2009.37_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1651-2227.2007.00199.x","article-title":"Glycosylation of therapeutic proteins in different production systems","volume":"96","author":"Werner","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1038\/mt.2009.37_bib32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0301-472X(03)00006-7","article-title":"Darbepoeitin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin","volume":"31","author":"Egrie","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1038\/mt.2009.37_bib33","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1210\/jc.2002-021201","article-title":"Glycosylation of an N-terminal extension prolongs the half-life and increased the in vivo activity of follicle stimulating hormone","volume":"88","author":"Perlman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/mt.2009.37_bib34","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/jps.20319","article-title":"Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins","volume":"94","author":"Sinclair","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1038\/mt.2009.37_bib35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/bit.20151","article-title":"Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"87","author":"Yamane-Ohnuki","year":"2004","journal-title":"Biotechnol Bioeng"},{"key":"10.1038\/mt.2009.37_bib36","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1345\/aph.1E334","article-title":"Insulin detemir\u2014a new basal insulin analog","volume":"39","author":"Goldman-Levine","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1038\/mt.2009.37_bib37","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/13543784.10.9.1725","article-title":"The place of pegvisomant in the management of acromegaly","volume":"10","author":"Parkinson","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1038\/mt.2009.37_bib38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Pegylated interferons: chemical and clinical differences","volume":"20","author":"Foster","year":"2004","journal-title":"Ailment Pharmacol Ther"},{"key":"10.1038\/mt.2009.37_bib39","doi-asserted-by":"crossref","first-page":"23203","DOI":"10.1074\/jbc.273.36.23203","article-title":"Purification and multimeric structure of bovine N-acetylglucosamine-1-phosphodiester \u03b1-N-acetylglucosaminidase","volume":"273","author":"Kornfeld","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.37_bib40","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M513717200","article-title":"Structural requirements for efficient processing and activation of recombinant human UDP-N-acetylglucosamine:lysosomal-enzyme-N-acetylglucosamine-1-phosphotransferase","volume":"281","author":"Kudo","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.37_bib41","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal neuropathologic and behavioral phenotype of 6neo\/6neo Pompe disease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1038\/mt.2009.37_bib42","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0405042101","article-title":"Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier","volume":"101","author":"Urayama","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.37_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1038\/mt.2009.37_bib44","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.37_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1023\/A:1026127307457","article-title":"Satellite cell depletion in degenerative skeletal muscle","volume":"8","author":"Jejurika","year":"2003","journal-title":"Apoptosis"},{"key":"10.1038\/mt.2009.37_bib46","first-page":"230","article-title":"Molecular mechanisms involving IGF-1 and myostatin to induce hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy","volume":"24","author":"Patel","year":"2005","journal-title":"Acta Myol"},{"key":"10.1038\/mt.2009.37_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1096\/fj.07-8673com","article-title":"Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice","volume":"22","author":"Nakatani","year":"2008","journal-title":"FASEB J"},{"key":"10.1038\/mt.2009.37_bib48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/abio.2002.5703","article-title":"Mannose 6-phosphate quantitation in glycoproteins using high-pH anion-exchange chromatography with pulsed amperometric detection","volume":"306","author":"Zhou","year":"2002","journal-title":"Anal Biochem"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616318019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616318019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T19:59:45Z","timestamp":1633204785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616318019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1525001616318019"],"URL":"https:\/\/doi.org\/10.1038\/mt.2009.37","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}